BlackRock backs UK life sciences firm in latest PE round

By Sam Kerr
11 Jan 2021

BlackRock, the US asset manager, has taken part in a $75m Series 'C' financing for Immunocore, a UK life sciences company that works in developing treatments that use the body’s T-cell receptors to fight cancer and other diseases.

Immunocore said the funding round, its third so far, was led by an existing shareholder and that numerous other shareholders took part alongside funds managed by BlackRock.

The company specialises in T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial